Contact Us
Drug Search Results
More Filters [+]

Nemolizumab

Alternative Names: nemolizumab, cim331, CD14152, CD-14152
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis.Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis.

Mechanisms of Action: IL31 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Japan

Approved Indications: None

Known Adverse Events: None

Company: Galderma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nemolizumab

Countries in Clinic: Australia, Austria, Belgium, Bulgaria, Canada, Czech Republic, Denmark, Estonia, France, Georgia, Germany, Hungary, Italy, Japan, Korea, Latvia, Lithuania, Netherlands, New Zealand, Poland, Singapore, Spain, Sweden, Switzerland, United Kingdom, United States

Active Clinical Trial Count: 32

Highest Development Phases

Phase 3: Dermatitis, Atopic|Kidney Diseases|Kidney Failure, Chronic|Neurodermatitis|Prurigo|Pruritus

Phase 2: Scleroderma, Diffuse|Scleroderma, General|Scleroderma, Systemic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
RD-06-SPR-202699

P3

Unknown Status

Prurigo

2027-08-15

jRCT2031230174

P3

Not yet recruiting

Dermatitis, Atopic|Pruritus

2027-04-30

RD.06.SPR.202699

P3

Active, not recruiting

Prurigo|Neurodermatitis

2026-10-26

RD.06.SPR.118163

P3

Unknown Status

Dermatitis, Atopic

2026-08-31

Recent News Events

Date

Type

Title

12/13/2024

News Article

 Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

12/13/2024

News Article

 CHMP Recommends Approval of Galderma's Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union

11/28/2024

News Article

 Galderma's Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis

10/24/2024

News Article

 Galderma Delivers Record Net Sales of 3.259 B USD in the First Nine Months of 2024, Demonstrates Significant Innovation Progress, Confirms and Narrows Its Full Year Net Sales Guidance

05/10/2024

PubMed

 Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA).

05/09/2024

PubMed

 Chronic Prurigo.

05/04/2024

PubMed

 Nemolizumab - a new key player in the treatment of prurigo nodularis.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions